The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) demonstrated that IL-1β blockade significantly reduced cardiovascular events, highlighting its relevance in post-traumatic myocardial injury [39]. This evidence concerns the gene IL1B and injury.